OncoMatch/Clinical Trials/NCT05650749
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
Is NCT05650749 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies GPC2 CAR T cells for refractory neuroblastoma.
Treatment: GPC2 CAR T cells — This is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma or retinoblastoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroblastoma
Disease stage
Required: Stage HIGH-RISK (COG), STAGE IVA, STAGE IVB (COG (Neuroblastoma), IRSS (Retinoblastoma))
Excluded: Stage STAGE III (RETINOBLASTOMA COHORT 1)
Metastatic disease required
high-risk neuroblastoma according to COG risk classification; metastatic retinoblastoma according to IRSS
Lab requirements
Kidney function
age-adjusted serum creatinine ≤1.5 ULN for age
Liver function
Total bilirubin ≤ 1.5 x ULN (exception: ≤ 3 ULN for Gilbert's Disease); AST/ALT ≤ 2.5 ULN (≤ 5 x ULN with liver metastases)
Cardiac function
LVSF ≥28% or LVEF ≥ 50% confirmed by Echo, or adequate ventricular function documented by a scan or a cardiologist
Total bilirubin ≤ 1.5 x ULN (exception: ≤ 3 ULN for Gilbert's Disease); AST/ALT ≤ 2.5 ULN (≤ 5 x ULN with liver metastases); age-adjusted serum creatinine ≤1.5 ULN for age; LVSF ≥28% or LVEF ≥ 50% confirmed by Echo, or adequate ventricular function documented by a scan or a cardiologist
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify